Physician profile
Simranjit Singh Bedi
NPI 1447678271
$12,489.16
in general payments reported to CMS, 2019-2025
32 companies · $3,630 in 2025
The $3,630 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $27.31 · 2021: $453 · 2022: $2,045 · 2023: $2,388 · 2024: $3,718 · 2025: $3,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,293 · Grant: $335 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,293.18 |
| Grant | $335.00 |
| Education | $108.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,353.83 | 2021-2025 | Skyrizi, Linzess, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $1,429.27 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,328.66 | 2021-2025 | Stelara, Tremfya, Remicade |
| Genzyme Corporation | $967.60 | 2022-2025 | |
| Gilead Sciences, INC. | $700.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $629.70 | 2021-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $543.80 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $496.65 | 2021-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $376.32 | 2024-2025 | Voquezna |
| Celgene Corporation | $370.06 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $364.69 | 2024-2025 | Zenpep, Vowst |
| Celltrion USA INC. | $351.38 | 2023-2025 | Vegzelma, Yuflyma |
| Ardelyx, INC. | $262.77 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $206.76 | 2021-2023 | |
| Lilly USA, LLC | $128.71 | 2024-2025 | Omvoh, Zepbound |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $125.00 | 2019 | |
| Madrigal Pharmaceuticals | $112.68 | 2025 | Rezdiffra |
| Pfizer INC. | $97.80 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $95.78 | 2021-2025 | |
| Braintree Laboratories, INC. | $90.82 | 2025 | Suflave |
| Ferring Pharmaceuticals INC. | $79.55 | 2022-2023 | Rebyota |
| Medtronic, INC. | $75.24 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.82 | 2023 | Cyltezo |
| Organon LLC | $46.82 | 2024 | |
| Merck Sharp & Dohme LLC | $45.07 | 2024 | Dificid, Zerbaxa, Recarbrio |
| Redhill Biopharma INC. | $33.81 | 2021-2022 | |
| Olympus America INC. | $27.31 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $20.49 | 2024 | Iqirvo |
| Daiichi Sankyo INC. | $19.29 | 2022 | |
| Shield Therapeutics INC | $18.46 | 2023 | Accrufer |
| Apollo Endosurgery US INC | $15.51 | 2022 | |
| Boston Scientific Corporation | $13.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simranjit Bedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.